Association between malnutrition and hyperhomocysteine in Alzheimer's disease patients and diet intervention of betaine

Journal of Clinical Laboratory Analysis

Volumn 31, Issue 5, 2017, Pages

  Sun, Jianying ^a   Wen, Shiling ^a   Zhou, Jing ^a   Ding, Shuling ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; betaine; hyperhomocysteine; malnutrition

Indexed keywords

AMYLOID BETA PROTEIN; BETAINE; HOMOCYSTEINE; INTERLEUKIN 1BETA; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE 2AC; TAU PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; NERVE PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; ASSAY; BIOACCUMULATION; COGNITION; CONTROLLED STUDY; DIETARY INTAKE; DISEASE ASSOCIATION; ENZYMATIC CYCLING ASSAY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; NUTRITIONAL ASSESSMENT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; BLOOD; CASE CONTROL STUDY; COMPLICATION; DEMENTIA; DIET THERAPY; DIETARY SUPPLEMENT; DRUG EFFECTS; MEMORY; METABOLISM; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BETAINE; CASE-CONTROL STUDIES; DEMENTIA; DIETARY SUPPLEMENTS; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MALNUTRITION; MEMORY; NERVE TISSUE PROTEINS; RISK FACTORS;

EID: 85029923062     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.22090     Document Type: Article

References (30)

1. Mi W, van Wijk N, Cansev M, Sijben JW, Kamphuis PJ. Nutritional approaches in the risk reduction and management of Alzheimer's disease. Nutrition. 2013;29:1080–1089.
2. Nazef K, Khelil M, Chelouti H, et al. Hyperhomocysteinemia is a risk factor for Alzheimer's disease in an Algerian population. Arch Med Res. 2014;45:247–250.
3. Wang M, Zhu Y, Shi Z, Li C, Shen Y. Meta-analysis of the relationship of peripheral retinal nerve fiber layer thickness to Alzheimer's disease and mild cognitive impairment. Shanghai Arch Psychiatry. 2015;27:263–279.
4. Zheng Z, Wang J, Yi L, et al. Correlation between behavioural and psychological symptoms of Alzheimer type dementia and plasma homocysteine concentration. BioMed Res Int. 2014;2014:383494.
5. Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Terro F. Tau protein phosphatases in Alzheimer's disease: the leading role of PP2A. Ageing Res Rev. 2013;12:39–49.
6. Lucke-Wold BP, Turner RC, Logsdon AF, Bailes JE, Huber JD, Rosen CL. Linking traumatic brain injury to chronic traumatic encephalopathy: identification of potential mechanisms leading to neurofibrillary tangle development. J Neurotrauma. 2014;31:1129–1138.
7. Farkas M, Keskitalo S, Smith DE, et al. Hyperhomocysteinemia in Alzheimer's disease: the hen and the egg? J Alzheimers Dis. 2013;33:1097–1104.
8. Olde Rikkert MG, Verhey FR, Sijben JW, et al. Differences in nutritional status between very mild Alzheimer's disease patients and healthy controls. J Alzheimers Dis. 2014;41:261–271.
9. Kamphuis PJ, Scheltens P. Can nutrients prevent or delay onset of Alzheimer's disease? J Alzheimers Dis. 2010;20:765–775.
10. Pocernich CB, Lange ML, Sultana R, Butterfield DA. Nutritional approaches to modulate oxidative stress in Alzheimer's disease. Curr Alzheimer Res. 2011;8:452–469.
11. Ousset PJ, Nourhashemi F, Reynish E, Vellas B. Nutritional status is associated with disease progression in very mild Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22:66–71.
12. Madsen SK, Rajagopalan P, Joshi SH, Toga AW, Thompson PM. Higher homocysteine associated with thinner cortical gray matter in 803 participants from the Alzheimer's Disease Neuroimaging Initiative. Neurobiol Aging. 2015;36(Suppl 1):S203–S210.
13. Huang CW, Chang WN, Huang SH, et al. Impact of homocysteine on cortical perfusion and cognitive decline in mild Alzheimer's dementia. Eur J Neurol. 2013;20:1191–1197.
14. Tu MC, Huang CW, Chen NC, et al. Hyperhomocysteinemia in Alzheimer dementia patients and cognitive decline after 6 months follow-up period. Acta Neurologica Taiwanica. 2010;19:168–177.
15. Cacciapuoti F. Lowering homocysteine levels with folic acid and B-vitamins do not reduce early atherosclerosis, but could interfere with cognitive decline and Alzheimer's disease. J Thromb Thrombolysis. 2013;36:258–262.
16. Rajdl D, Racek J, Trefil L, Stehlik P, Dobra J, Babuska V. Effect of folic acid, betaine, vitamin B(6), and vitamin B12 on homocysteine and dimethylglycine levels in middle-aged men drinking white wine. Nutrients. 2016;8:E34, doi: 10.3390/nu8010034.
17. Zhuo JM, Wang H, Pratico D. Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither? Trends Pharmacol Sci. 2011;32:562–571.
18. Craig SA. Betaine in human nutrition. Am J Clin Nutr. 2004;80:539–549.
19. Rullier L, Lagarde A, Bouisson J, Bergua V, Barberger-Gateau P. Nutritional status of community-dwelling older people with dementia: associations with individual and family caregivers’ characteristics. Int J Geriatr Psychiatry. 2013;28:580–588.
20. Droogsma E, van Asselt DZ, Scholzel-Dorenbos CJ, van Steijn JH, van Walderveen PE, van der Hooft CS. Nutritional status of community-dwelling elderly with newly diagnosed Alzheimer's disease: prevalence of malnutrition and the relation of various factors to nutritional status. J Nutr Health Aging. 2013;17:606–610.
21. Hooshmand B, Solomon A, Kareholt I, et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology. 2010;75:1408–1414.
22. Pacheco-Quinto J, Rodriguez de Turco EB, DeRosa S, et al. Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid beta peptide levels. Neurobiol Dis. 2006;22:651–656.
23. Ho YS, Yu MS, Yang XF, So KF, Yuen WH, Chang RC. Neuroprotective effects of polysaccharides from wolfberry, the fruits of Lycium barbarum, against homocysteine-induced toxicity in rat cortical neurons. J Alzheimers Dis. 2010;19:813–827.
24. Zhang CE, Tian Q, Wei W, et al. Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus. Neurobiol Aging. 2008;29:1654–1665.
25. Chai GS, Jiang X, Ni ZF, et al. Betaine attenuates Alzheimer-like pathological changes and memory deficits induced by homocysteine. J Neurochem. 2013;124:388–396.
26. Jin B, Gong Z, Yang N, et al. Downregulation of betaine homocysteine methyltransferase (BHMT) in hepatocellular carcinoma associates with poor prognosis. Tumour Biol. 2016;37:5911–5917.
27. Du YP, Peng JS, Sun A, Tang ZH, Ling WH, Zhu HL. Assessment of the effect of betaine on p16 and c-myc DNA methylation and mRNA expression in a chemical induced rat liver cancer model. BMC Cancer. 2009;9:261.
28. Ganesan B, Anandan R. Protective effect of betaine on changes in the levels of lysosomal enzyme activities in heart tissue in isoprenaline-induced myocardial infarction in Wistar rats. Cell Stress Chaperones. 2009;14:661–667.
29. Ganesan B, Anandan R, Lakshmanan PT. Studies on the protective effects of betaine against oxidative damage during experimentally induced restraint stress in Wistar albino rats. Cell Stress Chaperones. 2011;16:641–652.
30. Schiff M, Blom HJ. Treatment of inherited homocystinurias. Neuropediatrics. 2012;43:295–304.